GAMMA Investing LLC Has $22.10 Million Stake in Haleon plc (NYSE:HLN)

GAMMA Investing LLC increased its position in shares of Haleon plc (NYSE:HLN - Free Report) by 969.5% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 227,358 shares of the company's stock after acquiring an additional 206,100 shares during the quarter. GAMMA Investing LLC's holdings in Haleon were worth $22,095,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in HLN. Addison Advisors LLC raised its holdings in Haleon by 28.7% during the 4th quarter. Addison Advisors LLC now owns 4,954 shares of the company's stock worth $47,000 after purchasing an additional 1,106 shares during the last quarter. Haverford Trust Co grew its position in shares of Haleon by 5.0% during the 4th quarter. Haverford Trust Co now owns 25,842 shares of the company's stock worth $247,000 after buying an additional 1,233 shares during the period. Bessemer Group Inc. raised its stake in shares of Haleon by 5.9% during the fourth quarter. Bessemer Group Inc. now owns 22,301 shares of the company's stock worth $212,000 after buying an additional 1,236 shares during the last quarter. United Capital Financial Advisors LLC lifted its holdings in Haleon by 3.5% in the fourth quarter. United Capital Financial Advisors LLC now owns 37,475 shares of the company's stock valued at $358,000 after buying an additional 1,266 shares during the period. Finally, FIL Ltd boosted its stake in Haleon by 45.7% in the fourth quarter. FIL Ltd now owns 4,049 shares of the company's stock valued at $39,000 after acquiring an additional 1,270 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Haleon Trading Down 0.4%

NYSE:HLN traded down $0.05 on Friday, reaching $11.07. The company's stock had a trading volume of 13,897,070 shares, compared to its average volume of 8,750,126. Haleon plc has a 1-year low of $8.25 and a 1-year high of $11.42. The business's 50-day moving average price is $10.50 and its two-hundred day moving average price is $10.03. The firm has a market cap of $49.84 billion, a PE ratio of 32.56, a PEG ratio of 2.82 and a beta of 0.31. The company has a debt-to-equity ratio of 0.44, a quick ratio of 0.58 and a current ratio of 0.84.

Analyst Ratings Changes

Several analysts have commented on HLN shares. Deutsche Bank Aktiengesellschaft reiterated a "hold" rating on shares of Haleon in a research report on Monday, March 3rd. Wall Street Zen upgraded Haleon from a "hold" rating to a "buy" rating in a report on Friday. HSBC restated a "hold" rating on shares of Haleon in a report on Wednesday, March 5th. Morgan Stanley raised Haleon from an "equal weight" rating to an "overweight" rating and set a $11.25 price target for the company in a research note on Friday, May 9th. Finally, Barclays reiterated an "overweight" rating on shares of Haleon in a research report on Tuesday, May 6th. Five equities research analysts have rated the stock with a hold rating, five have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $12.33.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.